WO2025083549 - METHODS AND COMBINATIONS OF INHIBITORS OF IL-23 PATHWAY AND MODULATORS OF S1P SIGNALING PATHWAY FOR THE TREATMENT OF AUTOIMMUNE DISORDERS
National phase entry is expected:
Publication Number
WO/2025/083549
Publication Date
24.04.2025
International Application No.
PCT/IB2024/060098
International Filing Date
15.10.2024
Title **
[English]
METHODS AND COMBINATIONS OF INHIBITORS OF IL-23 PATHWAY AND MODULATORS OF S1P SIGNALING PATHWAY FOR THE TREATMENT OF AUTOIMMUNE DISORDERS
[French]
MÉTHODES ET COMBINAISONS D'INHIBITEURS DE LA VOIE IL-23 ET DE MODULATEURS DE LA VOIE DE SIGNALISATION S1P POUR LE TRAITEMENT DE MALADIES AUTO-IMMUNES
Applicants **
SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED
SUN PHARMACEUTICAL INDUSTRIES LIMITED
Inventors
CHIDREWAR, Gajanan
MANDHANE, Sanjay
RAMANATHAN, Vikram Krishna
Priority Data
202321070225
16.10.2023
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4169 | |
| EPO | Filing, Examination, Granting | 58203 | |
| Japan | Filing, Examination, Granting | 3988 | |
| South Korea | Filing, Examination, Granting | 5716 | |
| USA | Filing, Examination, Granting | 18540 |
Total:
90,616
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The disclosure relates to methods of treating autoimmune disorders or reducing or suppressing the symptoms of a chronic inflammatory disorder of the digestive tract using an inhibitor of the interleukin-23 signaling pathway and a modulator of the sphingosine-1- phosphate signaling pathway. The disclosure also relates to pharmaceutical compositions comprising an inhibitor of the interleukin-23 pathway and a modulator of the sphingosine-1- phosphate signaling pathway. The disclosure further relates to combinations of an inhibitor of the interleukin-23 signaling pathway and a modulator of the sphingosine-1-phosphate signaling pathway for use in the treatment of autoimmune disorders. The disclosure further relates to pharmaceutical kits comprising an inhibitor of the interleukin-23 signaling pathway, a modulator of the sphingosine-1-phosphate signaling pathway, and instructions for use. The disclosure further relates to the use of a combination of an inhibitor of the interleukin-23 signaling pathway and a modulator of the sphingosine-1-phosphate signaling pathway for the manufacture of a medicament for treating an autoimmune disorder.[French]
La divulgation concerne des méthodes de traitement de maladies auto-immunes ou de réduction ou de suppression des symptômes d'un trouble inflammatoire chronique du tractus digestif à l'aide d'un inhibiteur de la voie de signalisation de l'interleukine -23 et d'un modulateur de la voie de signalisation de la sphingosine-1-phosphate. La divulgation concerne également des compositions pharmaceutiques comprenant un inhibiteur de la voie de l'interleukine-23 et un modulateur de la voie de signalisation de la sphingosine-1-phosphate. La divulgation concerne en outre des combinaisons d'un inhibiteur de la voie de signalisation de l'interleukine-23 et d'un modulateur de la voie de signalisation de la sphingosine-1-phosphate destinée à être utilisée dans le traitement de maladies auto-immunes. La divulgation concerne en outre des trousses pharmaceutiques comprenant un inhibiteur de la voie de signalisation de l'interleukine-23, un modulateur de la voie de signalisation de la sphingosine-1-phosphate, et des instructions d'utilisation. La divulgation concerne en outre l'utilisation d'une combinaison d'un inhibiteur de la voie de signalisation de l'interleukine-23 et d'un modulateur de la voie de signalisation de la sphingosine-1-phosphate pour la fabrication d'un médicament pour le traitement d'une maladie auto-immune.